Webinar: Four Clinical Questions for Endocrinologist (CSEM)


1 hr




# of Credits



MOC - Section 1

Expiry Date


Individualization of diabetes care is a hallmark of its management. As the complexity of patients with diabetes increases and with the constant new stream of published evidence, endocrinologists and diabetologists can further adapt therapy based on the need of the patients seen in clinical practice. In this webinar, international diabetes experts will review the key evidence on four topics in clinical practice. This will include the impact of obesity, stroke, and frailty on diabetes management. Experts will discuss whether metformin should still be considered the first-line treatment option while other therapies may have more significant cardiorenal benefits.

This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.

This activity is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program, recognised in Europe by the European Accreditation Council for Continuing Medical Education and accredited by the Saudi Commission for Health Specialties for up 1.0 CPD.

Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.


David Strain, BSc(Hons), MB. ChB., MRCP(UK), MD, FRCP(London)

Matthias Blüher, MD

Alice Cheng, BSc(Hons), MD

Celine Huot, BSc(Hons), MD, FRCPC

Roopa Mehta, MBBS, MRCP

Saud Al Sifri, MD, FACE

Upon successful completion of this continuing education module, the participant will be better able to:

  1. Describe the role of obesity management on improving outcomes in type 2 diabetes
  2. Determine the role of antihyperglycemic agents in patients with type 2 diabetes and previous stroke
  3. Discuss the management of diabetes in the frail older adult
  4. List the pros and cons of using metformin as first-line therapy in patients with type 2 diabetes